2022 World Conference on Lung Cancer (ePosters)-EP02.01-007. Clinicopathologic and Prognostic Features of Early Resected Lung Adenocarcinoma Characterized With Uncommon EGFR Mutation

EP02.01-007. Clinicopathologic and Prognostic Features of Early Resected Lung Adenocarcinoma Characterized With Uncommon EGFR Mutation

Back to course

Pdf Summary

This study analyzed the clinical characteristics and prognostic effect of atypical EGFR mutations in patients with early resected lung adenocarcinoma (LUAD). The study included 511 patients and found that those with atypical EGFR mutations had a similar survival rate to those with classical EGFR mutations. However, among the atypical EGFR mutations, the L861Q mutation was found to be an independent prognostic factor for 487 patients. The study also examined the efficacy of adjuvant chemotherapy for these patients and found that it did not provide disease-free survival benefits, regardless of the stage of disease. <br /><br />The introduction of the study explained that there have been no prospective clinical trials that have evaluated the impact of adjuvant therapy in patients with atypical EGFR mutated NSCLC. This is due to the fact that the frequency and prognostic impact of atypical EGFR mutations have not been fully investigated. Therefore, this study aimed to investigate the clinical characteristics and prognostic effect of atypical EGFR mutations in patients with completely resected EGFR mutated LUAD, as well as whether adjuvant chemotherapy benefits these patients. <br /><br />The study utilized a retrospective review of 8,437 patients with invasive LUAD who underwent complete resection and EGFR mutation analysis. Propensity score matching (PSM) was conducted to compare the survival outcomes of patients with classical and atypical EGFR mutations. The prognostic significance of different atypical EGFR mutation subtypes and the impact of adjuvant chemotherapy were also analyzed. <br /><br />In conclusion, this study found that atypical EGFR mutations have a similar disease-free survival rate to classical mutations in patients with early resected LUAD. However, the L861Q mutation was associated with the poorest disease-free survival among the atypical EGFR mutations. Additionally, adjuvant chemotherapy did not provide disease-free survival benefits for patients with atypical EGFR mutations.

Asset Subtitle

Shenghui Li

Meta Tag

Speaker Shenghui Li

Topic Early Stage Non-small Cell Lung Cancer - Biomarkers

Keywords

clinical characteristics

prognostic effect

atypical EGFR mutations

early resected lung adenocarcinoma

LUAD

survival rate

L861Q mutation

independent prognostic factor

adjuvant chemotherapy

disease-free survival